Literature DB >> 19689230

Early diagnosis of Alzheimer's disease: is MCI too late?

Ronald C Petersen1.   

Abstract

The field of aging and dementia research is advancing rapidly toward the stage of earlier identification of clinical symptoms. Ultimately, clinicians would like to be able to identify individuals who are asymptomatic but at risk for developing dementia. In the interim, the construct of mild cognitive impairment (MCI) has come to represent an intermediate clinical state between the cognitive changes of aging and the very earliest features of Alzheimer's disease. A great deal of research has been generated in the past several years on MCI, and epidemiologic studies are characterizing its frequency in the general population. There are predictors of a more rapid progression from MCI to Alzheimer's disease, and these studies are suggesting techniques for altering future clinical trials. The neuropathology of MCI is intermediate between the neuropathologic changes of aging and fully developed Alzheimer's disease. The breadth of research in MCI is expanding and will be reviewed.

Entities:  

Mesh:

Year:  2009        PMID: 19689230      PMCID: PMC3098139          DOI: 10.2174/156720509788929237

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  28 in total

1.  Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.

Authors:  P J Visser; P Scheltens; F R Verhey; B Schmand; L J Launer; J Jolles; C Jonker
Journal:  J Neurol       Date:  1999-06       Impact factor: 4.849

2.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

3.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

Review 4.  Mild cognitive impairment.

Authors:  Serge Gauthier; Barry Reisberg; Michael Zaudig; Ronald C Petersen; Karen Ritchie; Karl Broich; Sylvie Belleville; Henry Brodaty; David Bennett; Howard Chertkow; Jeffrey L Cummings; Mony de Leon; Howard Feldman; Mary Ganguli; Harald Hampel; Philip Scheltens; Mary C Tierney; Peter Whitehouse; Bengt Winblad
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

5.  Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging.

Authors:  J C Morris; D W McKeel; M Storandt; E H Rubin; J L Price; E A Grant; M J Ball; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

6.  Neuropathologic features of amnestic mild cognitive impairment.

Authors:  Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Kris A Johnson; David S Knopman; Bradley F Boeve; Gregory A Jicha; Robert J Ivnik; Glenn E Smith; Eric G Tangalos; Heiko Braak; Emre Kokmen
Journal:  Arch Neurol       Date:  2006-05

7.  Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline.

Authors:  F Panza; C Capurso; A D'Introno; A M Colacicco; A Capurso; V Solfrizzi
Journal:  Neurology       Date:  2007-03-20       Impact factor: 9.910

8.  Conversion from subtypes of mild cognitive impairment to Alzheimer dementia.

Authors:  P Fischer; S Jungwirth; S Zehetmayer; S Weissgram; S Hoenigschnabl; E Gelpi; W Krampla; K H Tragl
Journal:  Neurology       Date:  2007-01-23       Impact factor: 9.910

9.  An epidemiologic study of mild cognitive impairment in Kolkata, India.

Authors:  S K Das; P Bose; A Biswas; A Dutt; T K Banerjee; A M Hazra; D K Raut; A Chaudhuri; T Roy
Journal:  Neurology       Date:  2007-06-05       Impact factor: 9.910

Review 10.  Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.

Authors:  Leslie M Shaw; Magdalena Korecka; Christopher M Clark; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Drug Discov       Date:  2007-03-09       Impact factor: 84.694

View more
  73 in total

Review 1.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 2.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

Review 3.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

Review 4.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

5.  Grey-matter volume as a potential feature for the classification of Alzheimer's disease and mild cognitive impairment: an exploratory study.

Authors:  Yane Guo; Zengqiang Zhang; Bo Zhou; Pan Wang; Hongxiang Yao; Minshao Yuan; Ningyu An; Haitao Dai; Luning Wang; Xi Zhang; Yong Liu
Journal:  Neurosci Bull       Date:  2014-04-23       Impact factor: 5.203

6.  Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment.

Authors:  J M Schott; J W Bartlett; J Barnes; K K Leung; S Ourselin; N C Fox
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

7.  The Framingham Brain Donation Program: neuropathology along the cognitive continuum.

Authors:  Rhoda Au; Sudha Seshadri; Kristen Knox; Alexa Beiser; Jayandra J Himali; Howard J Cabral; Sanford Auerbach; Robert C Green; Philip A Wolf; Ann C McKee
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

8.  A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor.

Authors:  Pengcheng Han; Geidy Serrano; Thomas G Beach; Richard J Caselli; Junxiang Yin; Ningning Zhuang; Jiong Shi
Journal:  J Neuropathol Exp Neurol       Date:  2017-01-01       Impact factor: 3.685

Review 9.  Smoking and increased Alzheimer's disease risk: a review of potential mechanisms.

Authors:  Timothy C Durazzo; Niklas Mattsson; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2014-06       Impact factor: 21.566

10.  A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.

Authors:  Hua Wang; Tessandra Stewart; Jon B Toledo; Carmen Ginghina; Lu Tang; Anzari Atik; Patrick Aro; Leslie M Shaw; John Q Trojanowski; Douglas R Galasko; Steven Edland; Poul H Jensen; Min Shi; Jing Zhang
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.